SLC5A2 and type 2 diabetes mellitus: The inhibitors of SGLT2 are the currently used drugs most recently added to the therapeutic armamentarium of T2DM, which have proven to have intriguing CV beneficial effects beyond the anti-hyperglycemic ones.